{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:48:34Z","timestamp":1790898514361,"version":"4.1.0"},"reference-count":155,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health","award":["RF-2018-12365509"],"award-info":[{"award-number":["RF-2018-12365509"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Lipids are not only constituents of cellular membranes, but they are also key signaling mediators, thus acting as \u201cbioactive lipids\u201d. Among the prominent roles exerted by bioactive lipids are immune regulation, inflammation, and maintenance of homeostasis. Accumulated evidence indicates the existence of a bidirectional relationship between the immune and nervous systems, and lipids can interact particularly with the aggregation and propagation of many pathogenic proteins that are well-renowned hallmarks of several neurodegenerative disorders, including Alzheimer\u2019s (AD) and Parkinson\u2019s (PD) diseases. In this review, we summarize the current knowledge about the presence and quantification of the main classes of endogenous bioactive lipids, namely glycerophospholipids\/sphingolipids, classical eicosanoids, pro-resolving lipid mediators, and endocannabinoids, in AD and PD patients, as well as their most-used animal models, by means of lipidomic analyses, advocating for these lipid mediators as powerful biomarkers of pathology, diagnosis, and progression, as well as predictors of response or activity to different current therapies for these neurodegenerative diseases.<\/jats:p>","DOI":"10.3390\/ijms23116235","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T11:05:02Z","timestamp":1654167902000},"page":"6235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Lipidomics of Bioactive Lipids in Alzheimer\u2019s and Parkinson\u2019s Diseases: Where Are We?"],"prefix":"10.3390","volume":"23","author":[{"given":"Valerio","family":"Chiurchi\u00f9","sequence":"first","affiliation":[{"name":"Institute of Translational Pharmacology, National Research Council, 00179 Rome, Italy"},{"name":"Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Tiberi","sequence":"additional","affiliation":[{"name":"Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Matteocci","sequence":"additional","affiliation":[{"name":"Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Fazio","sequence":"additional","affiliation":[{"name":"Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasibullah","family":"Siffeti","sequence":"additional","affiliation":[{"name":"Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"},{"name":"Institute for Nutritional Medicine, University Medical Centre Schleswig Holstein, 23562 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Saracini","sequence":"additional","affiliation":[{"name":"Laboratory of Resolution of Neuroinflammation, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6700-7491","authenticated-orcid":false,"given":"Nicola Biagio","family":"Mercuri","sequence":"additional","affiliation":[{"name":"Neurology Unit, Tor Vergata Hospital, 00133 Rome, Italy"},{"name":"Department of Experimental Neuroscience, IRCCS Santa Lucia Foundation, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1772-9012","authenticated-orcid":false,"given":"Giuseppe","family":"Sancesario","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Tor Vergata University of Rome, 00179 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.plipres.2005.08.001","article-title":"The significance of lipid composition for membrane activity: New concepts and ways of assessing function","volume":"44","author":"Vigh","year":"2005","journal-title":"Prog. Lipid Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.011008.145616","article-title":"Lipid mediators in health and disease: Enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation","volume":"49","author":"Shimizu","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.coph.2016.06.005","article-title":"Bioactive lipids as modulators of immunity, inflammation and emotions","volume":"29","author":"Maccarrone","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fimmu.2018.00038","article-title":"Bioactive Lipids and Chronic Inflammation: Managing the Fire within","volume":"9","author":"Leuti","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: Lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2006.04.004","article-title":"Bioactive sphingolipids in the modulation of the inflammatory response","volume":"112","author":"Wu","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/can.2016.0002","article-title":"Endocannabinoids and Immunity","volume":"1","year":"2016","journal-title":"Cannabis. Cannabinoid. Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kao, Y.C., Ho, P.C., Tu, Y.K., Jou, I.M., and Tsai, K.J. (2020). Lipids and Alzheimer\u2019s Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041505"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1523\/JNEUROSCI.5543-03.2004","article-title":"Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"24","author":"Kawarabayashi","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_12","first-page":"2181","article-title":"Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer\u2019s disease","volume":"150","author":"Wilson","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1073\/pnas.89.5.1671","article-title":"Evidence for a membrane defect in Alzheimer disease brain","volume":"89","author":"Nitsch","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neurobiolaging.2013.08.001","article-title":"Evidence of altered phosphatidylcholine metabolism in Alzheimer\u2019s disease","volume":"35","author":"Whiley","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.3466","article-title":"Plasma phospholipids identify antecedent memory impairment in older adults","volume":"20","author":"Mapstone","year":"2014","journal-title":"Nat. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jalz.2016.08.003","article-title":"Association of blood lipids with Alzheimer\u2019s disease: A comprehensive lipidomics analysis","volume":"13","author":"Proitsi","year":"2017","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0305799101","article-title":"Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer\u2019s disease","volume":"101","author":"Cutler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2017.06.008","article-title":"Alzheimer\u2019s brains show inter-related changes in RNA and lipid metabolism","volume":"106","author":"Barbash","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Varma, V.R., Oommen, A.M., Varma, S., Casanova, R., An, Y., Andrews, R.M., O\u2019Brien, R., Pletnikova, O., Troncoso, J.C., and Toledo, J. (2018). Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. PLoS Med., 15.","DOI":"10.1371\/journal.pmed.1002482"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3233\/JAD-2011-111202","article-title":"Increased ceramide in brains with Alzheimer\u2019s and other neurodegenerative diseases","volume":"29","author":"Filippov","year":"2012","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.neuroscience.2004.08.056","article-title":"Astroglial expression of ceramide in Alzheimer\u2019s disease brains: A role during neuronal apoptosis","volume":"130","author":"Satoi","year":"2005","journal-title":"Neuroscience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1046\/j.1471-4159.2002.00997.x","article-title":"Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer\u2019s disease: Potential role in disease pathogenesis","volume":"82","author":"Han","year":"2002","journal-title":"J. Neurochem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neurobiolaging.2008.03.011","article-title":"Serum sphingomyelins and ceramides are early predictors of memory impairment","volume":"31","author":"Mielke","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","article-title":"Deregulation of sphingolipid metabolism in Alzheimer\u2019s disease","volume":"31","author":"He","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1743-8454-6-10","article-title":"The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid","volume":"6","author":"Harrington","year":"2009","journal-title":"Cerebrospinal. Fluid Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"611393","DOI":"10.3389\/fnins.2020.611393","article-title":"Accumulation of Cerebrospinal Fluid Glycerophospholipids and Sphingolipids in Cognitively Healthy Participants With Alzheimer\u2019s Biomarkers Precedes Lipolysis in the Dementia Stage","volume":"14","author":"Fonteh","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3233\/JAD-122224","article-title":"Plasma fatty acid lipidomics in amnestic mild cognitive impairment and Alzheimer\u2019s disease","volume":"36","author":"Iuliano","year":"2013","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1023\/A:1022457605436","article-title":"Regional membrane phospholipid alterations in Alzheimer\u2019s disease","volume":"23","author":"Prasad","year":"1998","journal-title":"Neurochem. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0197-0186(92)90147-J","article-title":"Decreased prostaglandin synthesis in postmortem cerebral cortex from patients with Alzheimer\u2019s disease","volume":"21","author":"Wong","year":"1992","journal-title":"Neurochem. Int."},{"key":"ref_30","first-page":"2165","article-title":"Gas chromatography-mass spectrometry analysis of the free fatty acids in serum obtained from patients with Alzheimer\u2019s disease","volume":"26","author":"Cui","year":"2015","journal-title":"Biomed. Mater. Eng."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3233\/JAD-2010-1242","article-title":"Lipid alterations in lipid rafts from Alzheimer\u2019s disease human brain cortex","volume":"19","author":"Fabelo","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Snowden, S.G., Ebshiana, A.A., Hye, A., An, Y., Pletnikova, O., O\u2019Brien, R., Troncoso, J., Legido-Quigley, C., and Thambisetty, M. (2017). Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: Anontargeted metabolomic study. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002266"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Astarita, G., Jung, K.M., Berchtold, N.C., Nguyen, V.Q., Gillen, D.L., Head, E., Cotman, C.W., and Piomelli, D. (2010). Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer\u2019s disease. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012538"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.plefa.2011.04.021","article-title":"Towards a whole-body systems [multi-organ] lipidomics in Alzheimer\u2019s disease","volume":"85","author":"Astarita","year":"2011","journal-title":"Leukot. Essent. Fat. Acids"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1476-511X-12-68","article-title":"Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein\/tau for Alzheimer\u2019s disease","volume":"12","author":"Tajima","year":"2013","journal-title":"Lipids Health Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-2004-6405","article-title":"Reduction of brain lipid peroxidation by CSF drainage in Alzheimer\u2019s disease patients","volume":"6","author":"Yao","year":"2004","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"104519","DOI":"10.1016\/j.neuint.2019.104519","article-title":"Lipid peroxidation biomarkers correlation with medial temporal atrophy in early Alzheimer Disease","volume":"129","author":"Cuevas","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"510","DOI":"10.5858\/2001-125-0510-CFATAF","article-title":"Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls","volume":"125","author":"Montine","year":"2001","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Trushina, E., Dutta, T., Persson, X.M., Mielke, M.M., and Petersen, R.C. (2013). Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer\u2019s disease using metabolomics. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063644"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Biringer, R.G. (2019). The Role of Eicosanoids in Alzheimer\u2019s Disease. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16142560"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF00314401","article-title":"The formation of prostaglandins in the postmortem cerebral cortex of Alzheimer-type dementia patients","volume":"236","author":"Iwamoto","year":"1989","journal-title":"J. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/WNL.53.7.1495","article-title":"Elevated CSF prostaglandin E2 levels in patients with probable AD","volume":"53","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Ferr\u00e9-Gonz\u00e1lez, L., Pe\u00f1a-Bautista, C., Baquero, M., and Ch\u00e1fer-Peric\u00e1s, C. (2022). Assessment of Lipid Peroxidation in Alzheimer\u2019s Disease Differential Diagnosis and Prognosis. Antioxidants, 11.","DOI":"10.3390\/antiox11030551"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.brainresbull.2004.04.016","article-title":"Increased urinary F(2)-isoprostanes levels in the patients with Alzheimer\u2019s disease","volume":"64","author":"Kim","year":"2004","journal-title":"Brain Res. Bull."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1172\/JCI25420","article-title":"A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease","volume":"115","author":"Lukiw","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Calon, F., Julien, C., Winkler, J.W., Petasis, N.A., Lukiw, W.J., and Bazan, N.G. (2011). Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR\u03b3-mediated mechanisms in Alzheimer\u2019s disease models. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0015816"},{"key":"ref_47","first-page":"40","article-title":"Resolution of inflammation is altered in Alzheimer\u2019s disease. Alzheimer\u2019s Dement","volume":"11","author":"Wang","year":"2015","journal-title":"J. Alzheimer\u2019s Assoc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s12035-015-9544-0","article-title":"Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase A\u03b242 Phagocytosis","volume":"53","author":"Zhu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/s41467-018-03674-2","article-title":"Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer\u2019s Disease","volume":"9","author":"Lee","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Do, K.V., Hjorth, E., Wang, Y., Jun, B., Kautzmann, M.I., Ohshima, M., Eriksdotter, M., Schultzberg, M., and Bazan, N.G. (2022). Cerebrospinal Fluid Profile of Lipid Mediators in Alzheimer\u2019s Disease. Cell Mol. Neurobiol.","DOI":"10.21203\/rs.3.rs-1029034\/v2"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1007\/s00018-006-6037-3","article-title":"Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels","volume":"63","author":"Mazzola","year":"2006","journal-title":"Cell Mol. Life Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22429","DOI":"10.1038\/srep22429","article-title":"NO2 inhalation promotes Alzheimer\u2019s disease-like progression: Cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication","volume":"6","author":"Yan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3233\/JAD-142349","article-title":"Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer\u2019s Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline","volume":"46","author":"Altamura","year":"2015","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.neurobiolaging.2011.03.012","article-title":"An amyloid \u03b242-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer\u2019s disease","volume":"33","author":"Jung","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.celrep.2012.05.001","article-title":"A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer\u2019s Disease","volume":"1","author":"Piro","year":"2012","journal-title":"Cell Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.celrep.2012.09.030","article-title":"Monoacylglycerol lipase is a therapeutic target for Alzheimer\u2019s disease","volume":"2","author":"Chen","year":"2012","journal-title":"Cell Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/JAD-131961","article-title":"Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the A\u03b2PPswe\/PS1\u0394E9 mouse model of Alzheimer\u2019s disease","volume":"42","author":"Maroof","year":"2014","journal-title":"J. Alzheimer\u2019s Dis. JAD"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3233\/JAD-171036","article-title":"Alterations in the plasma levels of specific choline phospholipids in Alzheimer\u2019s disease mimic accelerated aging","volume":"62","author":"Dorninger","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1023\/A:1011603916962","article-title":"Brain membrane phospholipid alterations in Alzheimer\u2019s disease","volume":"26","author":"Pettegrew","year":"2001","journal-title":"Neurochem. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1042\/bst0320144","article-title":"Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer\u2019s disease","volume":"32","author":"Alessenko","year":"2004","journal-title":"Biochem. Soc. Trans."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2014.01.010","article-title":"Ceramides and sphingomyelinases in senile plaques","volume":"65","author":"Panchal","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-018-0527-z","article-title":"Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer\u2019s disease brain","volume":"6","author":"Dominguez","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Fonteh, A.N., Cipolla, M., Chiang, J., Arakaki, X., and Harrington, M.G. (2014). Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer\u2019s disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100519"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Solomon, V., Hafez, M., Xian, H., Harrington, M., Fonteh, A., and Yassine, H. (2022). An Association Between Saturated Fatty Acid-Containing Phosphatidylcholine in Cerebrospinal Fluid with Tau Phosphorylation. J. Alzheimer\u2019s Dis., Epub ahead of print.","DOI":"10.3233\/JAD-215643"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1079\/BJN2002804","article-title":"Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer\u2019s disease: A case-control study","volume":"89","author":"Tully","year":"2003","journal-title":"Br. J. Nutr."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.abb.2018.12.027","article-title":"Interactions of polyunsaturated fatty acids with amyloid peptides Abeta40 and AbetaArch","volume":"663","author":"Pham","year":"2019","journal-title":"Biochem. Biophys."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuint.2010.12.004","article-title":"Effects of fatty acid unsaturation numbers on membrane fluidity and alpha-secretase-dependent amyloid precursor protein processing","volume":"58","author":"Yang","year":"2011","journal-title":"Neurochem. Int."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3945\/ajcn.2008.26987","article-title":"Omega-3 fatty acids and risk of dementia: The Canadian Study of Health and Aging","volume":"90","author":"Kroger","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11064-009-0087-5","article-title":"Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer\u2019s disease","volume":"35","author":"Fraser","year":"2010","journal-title":"Neurochem. Res."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chu, C.S., Hung, C.F., Ponnusamy, V.K., Chen, K.C., and Chen, N.C. (2022). Higher Serum DHA and Slower Cognitive Decline in Patients with Alzheimer\u2019s Disease: Two-Year Follow-Up. Nutrients, 14.","DOI":"10.3390\/nu14061159"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.freeradbiomed.2018.02.019","article-title":"Analysis of eicosanoid oxidation products in Alzheimer brain by LC-MS with uniformly 13C-labeled internal standards","volume":"118","author":"Furman","year":"2018","journal-title":"Free Radic. Biol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000107699","article-title":"Plasma F2A isoprostane levels in Alzheimer\u2019s and Parkinson\u2019s disease","volume":"4","author":"Irizarry","year":"2007","journal-title":"Neurodegener. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ana.10272","article-title":"Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer\u2019s disease","volume":"52","author":"Montine","year":"2002","journal-title":"Ann. Neurol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"747","DOI":"10.3109\/00207454.2014.971787","article-title":"Cerebrospinal fluid biomarkers for neuropsychological symptoms in early stage of late-onset Alzheimer\u2019s disease","volume":"125","author":"Kuo","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jpba.2014.05.023","article-title":"Metabolomic study of lipids in serum for biomarker discovery in Alzheimer\u2019s disease using direct infusion mass spectrometry","volume":"98","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/jnnp.2005.063131","article-title":"Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer\u2019s disease","volume":"77","author":"Combrinck","year":"2006","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.neurobiolaging.2005.12.011","article-title":"Determinants of platelet activation in Alzheimer\u2019s disease","volume":"28","author":"Ciabattoni","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Montine, T.J., Sonnen, J.A., Milne, G., Baker, L.D., and Breitner, J.C. (2010). Elevated ratio of urinary metabolites of thromboxane and prostacyclin is associated with adverse cardiovascular events in ADAPT. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009340"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3233\/JAD-141335","article-title":"Restoration of Lipoxin A4 Signaling Reduces Alzheimer\u2019s Disease-Like Pathology in the 3xTg-AD Mouse Model","volume":"43","author":"Dunn","year":"2014","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.expneurol.2017.11.005","article-title":"Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer\u2019s disease","volume":"300","author":"Kantarci","year":"2018","journal-title":"Exp. Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1194\/jlr.P055418","article-title":"Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: The OmegAD study","volume":"56","author":"Wang","year":"2015","journal-title":"J. Lipid Res."},{"key":"ref_82","first-page":"2681","article-title":"\u03c9-3 Supplementation increases amyloid-\u03b2 phagocytosis and resolvin D1 in patients with minor cognitive impairment","volume":"29","author":"Fiala","year":"2015","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbi.2017.11.002","article-title":"Fish oil feeding attenuates neuroinflammatory gene expression without concomitant changes in brain eicosanoids and docosanoids in a mouse model of Alzheimer\u2019s disease","volume":"69","author":"Hopperton","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1096\/fj.201800200R","article-title":"Cerebrovascular \u03b2-amyloid deposition and associated microhemorrhages in a Tg2576 Alzheimer mouse model are reduced with a DHA-enriched diet","volume":"32","author":"Hur","year":"2018","journal-title":"FASEB J."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1476-511X-8-2","article-title":"Endocannabinoids in Alzheimer\u2019s disease and their impact on normative cognitive performance: A case-control and cohort study","volume":"8","author":"Koppel","year":"2009","journal-title":"Lipids Health Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1007\/s00216-017-0300-3","article-title":"A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples","volume":"409","author":"Marchioni","year":"2017","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/mds.27115","article-title":"Past, present, and future of Parkinson\u2019s disease: A special essay on the 200th Anniversary of the Shaking Palsy","volume":"32","author":"Obeso","year":"2017","journal-title":"Mov. Disord."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Sarchione, A., Marchand, A., Taymans, J.-M., and Chartier-Harlin, M.-C. (2021). Alpha-Synuclein and Lipids: The Elephant in the Room?. Cells, 10.","DOI":"10.3390\/cells10092452"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1126\/science.1090389","article-title":"Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein","volume":"302","author":"Willingham","year":"2003","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00441-016-2463-1","article-title":"Mitochondrial lipids in neurodegeneration","volume":"367","author":"Aufschnaiter","year":"2017","journal-title":"Cell Tissue Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Riboldi, G.M., and Di Fonzo, A.B. (2019). GBA, Gaucher Disease, and Parkinson\u2019s Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells, 8.","DOI":"10.3390\/cells8040364"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Fais, M., Dore, A., Galioto, M., Galleri, G., Crosio, C., and Iaccarino, C. (2021). Parkinson\u2019s Disease-Related Genes and Lipid Alteration. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147630"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41531-021-00241-3","article-title":"Glucosylceramide in cerebrospinal fluid of patients with GBA-associated and idiopathic Parkinson\u2019s disease en-rolled in PPMI","volume":"7","author":"Huh","year":"2021","journal-title":"NPJ Park. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Mielke, M.M., Maetzler, W., Haughey, N.J., Bandaru, V.R., Savica, R., Deutschle, C., Gasser, T., Hauser, A.H., Gr\u00e4-ber-Sultan, S., and Liepelt-Scarfone, I. (2013). Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson\u2019s Disease and Associated with Cognitive Impairment: A Pilot Study. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073094"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/brain\/awab371","article-title":"Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation","volume":"371","author":"Galvagnion","year":"2022","journal-title":"Brain Awab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bbrc.2016.08.082","article-title":"LRRK2 deficiency im-pacts ceramide metabolism in brain","volume":"478","author":"Ferrazza","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1021\/acs.jproteome.1c00374","article-title":"Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson\u2019s Disease","volume":"20","author":"Tatlay","year":"2021","journal-title":"J. Proteome Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.celrep.2019.10.035","article-title":"Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson\u2019s Disease","volume":"29","author":"Hertel","year":"2019","journal-title":"Cell Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"18865","DOI":"10.3390\/ijms160818865","article-title":"Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson\u2019s Disease","volume":"16","author":"Farmer","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Xicoy, H., Brouwers, J.F., Wieringa, B., and Martens, G.J.M. (2020). Explorative Combined Lipid and Transcriptomic Profiling of Substantia Nigra and Putamen in Parkinson\u2019s Disease. Cells, 9.","DOI":"10.3390\/cells9091966"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Beger, A.W., Dudzik, B., Woltjer, R.L., and Wood, P.L. (2022). Human Brain Lipidomics: Pilot Analysis of the Basal Ganglia Sphingolipidome in Parkinson\u2019s Disease and Lewy Body Disease. Metabolites, 12.","DOI":"10.3390\/metabo12020187"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/mds.25729","article-title":"Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson\u2019s disease","volume":"29","author":"Abbott","year":"2014","journal-title":"Mov. Disord."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1759091418781889","DOI":"10.1177\/1759091418781889","article-title":"Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson\u2019s Disease","volume":"10","author":"Seyfried","year":"2018","journal-title":"ASN Neuro."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e17299","DOI":"10.1371\/journal.pone.0017299","article-title":"Lipid pathway alterations in Parkinson\u2019s disease primary visual cortex","volume":"6","author":"Cheng","year":"2011","journal-title":"PLoS ONE"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Irigoyen, J., Cartas-Cejudo, P., Iruarrizaga-Lejarreta, M., and Santamar\u00eda, E. (2021). Alteration in the Cerebrospinal Fluid Lipidome in Parkinson\u2019s Disease: A Post-Mortem Pilot Study. Biomedicines, 9.","DOI":"10.20944\/preprints202104.0324.v1"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41467-021-21669-4","article-title":"Metabolomics of sebum reveals lipid dysregulation in Parkinson\u2019s disease","volume":"12","author":"Sinclair","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/jcp.25815","article-title":"Lipid profiling of parkin-mutant human skin fibroblasts","volume":"232","author":"Lobasso","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"49874","DOI":"10.1074\/jbc.M309127200","article-title":"Altered Fatty Acid Composition of Dopaminergic Neurons Expressing alpha-synuclein and human brains with \u03b1-Synucleinopathies","volume":"278","author":"Sharon","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2119\/molmed.2011.00119","article-title":"Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson\u2019s disease and incidental Parkinson\u2019s disease","volume":"17","author":"Fabelo","year":"2011","journal-title":"Mol. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e4781","DOI":"10.1002\/jms.4781","article-title":"Targeted fatty acid metabolomics to discover Parkinson\u2019s disease associated metabolic alteration","volume":"56","author":"Zhang","year":"2021","journal-title":"J. Mass Spectrom."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jchromb.2018.01.025","article-title":"Potential biomarkers of Parkinson\u2019s disease revealed by plasma metabolic profiling","volume":"1081\u20131082","author":"Zhao","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neulet.2007.12.031","article-title":"Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia","volume":"432","author":"Golovko","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1039\/c4mt00022f","article-title":"Manganese leads to an increase in markers of oxidative stress as well as to a shift in the ratio of Fe(ii)\/(iii) in rat brain tissue","volume":"6","author":"Fernsebner","year":"2014","journal-title":"Metallomics"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.freeradbiomed.2009.11.026","article-title":"Oxidative damage in Parkinson disease: Measurement using accurate biomarkers","volume":"48","author":"Seet","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/10715762.2015.1005085","article-title":"LC\/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: Implication for mitochondrial dysfunction in Parkinson\u2019s disease","volume":"49","author":"Tyurina","year":"2015","journal-title":"Free Radic. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/mds.28186","article-title":"High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson\u2019s Disease","volume":"35","author":"Valek","year":"2020","journal-title":"Mov. Disord."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1096\/fasebj.14.10.1432","article-title":"Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson\u2019s disease","volume":"14","author":"Hill","year":"2000","journal-title":"FASEB J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1523\/JNEUROSCI.22-16-06900.2002","article-title":"Experimental parkinsonism alters endocannabinoid degradation: Implications for striatal glutamatergic transmission","volume":"22","author":"Gubellini","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1046\/j.1471-4159.2003.01759.x","article-title":"Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism","volume":"4","author":"Maccarrone","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1046\/j.1460-9568.2003.02896.x","article-title":"Effects of levodopa on endocannabinoid levels in rat basal ganglia: Implications for the treatment of levodopa-induced dyskinesias","volume":"6","author":"Ferrer","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbr.2018.03.020","article-title":"Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson\u2019s disease by metabolomic technology","volume":"347","author":"Wang","year":"2018","journal-title":"Behav. Brain Res."},{"key":"ref_122","first-page":"1140","article-title":"A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson\u2019s disease","volume":"9","author":"Fox","year":"2005","journal-title":"FASEB J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1126\/science.1209200","article-title":"Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation","volume":"6057","author":"Nomura","year":"2011","journal-title":"Science"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.expneurol.2015.07.024","article-title":"Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson\u2019s disease","volume":"273","author":"Mounsey","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.expneurol.2015.04.007","article-title":"Differential upregulation of the cannabinoid CB2 receptor in neurotoxic and inflammation-driven rat models of Parkinson\u2019s disease","volume":"269","author":"Concannon","year":"2015","journal-title":"Exp. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.expneurol.2016.06.014","article-title":"Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson\u2019s disease","volume":"283","author":"Concannon","year":"2016","journal-title":"Exp. Neurol."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Kelly, R., Bemelmans, A.P., Jos\u00e9phine, C., Brouillet, E., McKernan, D.P., and Dowd, E. (2022). Time-Course of Alterations in the Endocannabinoid System after Viral-Mediated Overexpression of \u03b1-Synuclein in the Rat Brain. Molecules, 507.","DOI":"10.3390\/molecules27020507"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1038\/s41467-019-11928-w","article-title":"Blunting neuroinflammation with resolvin D1 prevents early pathology in a rat model of Parkinson\u2019s disease","volume":"10","author":"Krashia","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.neuropharm.2015.10.021","article-title":"Dopamine-dependent CB1 receptor dysfunction at corticostriatal synapses in homozygous PINK1 knockout mice","volume":"101","author":"Madeo","year":"2016","journal-title":"Neuropharmacology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00702-020-02240-9","article-title":"Endocannabinoid levels in patients with Parkinson\u2019s disease with and without levodopa-induced dyskinesias","volume":"10","author":"Marchioni","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"121809","DOI":"10.1016\/j.jchromb.2019.121809","article-title":"Determination of anandamide in cerebrospinal fluid samples by disposable pipette extraction and ultra-high performance liquid chromatography tandem mass spectrometry","volume":"1130","author":"Oliveira","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"461766","DOI":"10.1016\/j.chroma.2020.461766","article-title":"In-tube solid-phase microextraction directly coupled to tandem mass spectrometry for anandamide and 2-arachidonoylglycerol determination in rat brain samples from an animal model of Parkinson\u2019s disease","volume":"1636","author":"Oliveira","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tem.2018.11.003","article-title":"Sphingolipids in the Pathogenesis of Parkinson\u2019s Disease and Parkinsonism","volume":"30","author":"Lin","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"829291","DOI":"10.3389\/fnmol.2022.829291","article-title":"Lipid Homeostasis and its Links with Protein Misfolding Diseases","volume":"15","author":"Vendruscolo","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson\u2019s Disease","volume":"361","author":"Nalls","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3233\/JPD-202310","article-title":"Cerebrospinal Fluid Profiles in Parkinson\u2019s Disease: No Accumulation of Glucosylceramide, but Significant Downregulation of Active Complement C5 Fragment","volume":"11","author":"Niimi","year":"2021","journal-title":"J. Parkinsons. Dis."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tins.2006.03.006","article-title":"LRRK2 in Parkinson\u2019s disease: Protein domains and functional insights","volume":"29","author":"Mata","year":"2006","journal-title":"Trends Neurosci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-1326-7-25","article-title":"LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors","volume":"7","author":"Hinkle","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JPD-202476","article-title":"Lipidomics Predic-tion of Parkinson\u2019s Disease Severity: A Machine-Learning Analysis","volume":"11","author":"Avisar","year":"2021","journal-title":"J. Parkinsons. Dis."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mds.26278","article-title":"No evidence for substrate accumulation in Parkinson brains with GBA mutations","volume":"30","author":"Gegg","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson\u2019s disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat. Neurosci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1039\/C8AN01778F","article-title":"An NMR-based lipidomic approach to identify Parkinson\u2019s disease-stage specific lipoprotein-lipid signatures in plasma","volume":"144","author":"Pizarro","year":"2019","journal-title":"Analyst"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1046\/j.1471-4159.1995.64041645.x","article-title":"Prostaglandin H Synthetase-Mediated Metabolism of Dopamine: Implication for Parkinson\u2019s Disease","volume":"64","author":"Mattammal","year":"1995","journal-title":"J. Neurochem."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Yu, S., Zou, L., Wang, F., Chen, Z., Hu, Y., Wang, Y., Wang, X., and Zhang, W. (2014). Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: A cross-sectional study. BMC Neurol., 14.","DOI":"10.1186\/1471-2377-14-113"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.neuro.2015.12.007","article-title":"DJ-1 mutation decreases astroglial release of inflammatory mediators","volume":"52","author":"Ashley","year":"2016","journal-title":"Neurotoxicology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nbd.2019.04.003","article-title":"A Parkinson\u2019s disease gene, DJ-1, regulates anti-inflammatory roles of astrocytes through prostaglandin D2 synthase expression","volume":"127","author":"Choi","year":"2019","journal-title":"Neurobiol. Dis."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3892\/mmr.2015.3494","article-title":"Somatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia","volume":"12","author":"Bai","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/glia.20294","article-title":"Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity","volume":"53","author":"McLaughlin","year":"2006","journal-title":"Glia"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.neuropharm.2013.06.014","article-title":"Protection of dopaminergic neurons by 5-lipoxygenase inhibitor","volume":"73","author":"Kang","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbr.2009.11.020","article-title":"Striatal 6-OHDA lesion in mice: Investigating early neurochemical changes underlying Parkinson\u2019s disease","volume":"208","author":"Branchi","year":"2010","journal-title":"Behav. Brain Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ana.20462","article-title":"High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson\u2019s disease patients","volume":"57","author":"Pisani","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/mds.23014","article-title":"Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson\u2019s disease patients","volume":"7","author":"Pisani","year":"2010","journal-title":"Mov. Disord."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/mds.23457","article-title":"Homeostatic changes of the endocannabinoid system in Parkinson\u2019s disease","volume":"2","author":"Pisani","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"122351","DOI":"10.1016\/j.jchromb.2020.122351","article-title":"A micro salting-out assisted liquid-liquid extraction combined with ultra-high performance liquid chromatography tandem mass spectrometry to determine anandamide and 2-arachidonoylglycerol in rat brain samples","volume":"1158","author":"Oliveira","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100894","DOI":"10.1016\/j.mam.2020.100894","article-title":"The Atlas of Inflammation Resolution (AIR)","volume":"74","author":"Serhan","year":"2020","journal-title":"Mol Aspects Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/6235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:23:53Z","timestamp":1760138633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/11\/6235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":155,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["ijms23116235"],"URL":"https:\/\/doi.org\/10.3390\/ijms23116235","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]}}}